Consider OPT and the jump it had post successful phase 2 trial...there is no reason that bot couldn't do the same. Similar MC.
One could certainly argue that bot has a much superior market opportunity in acne should the drug btx1503 be shown to be effective...nevermind the other drugs in the pipeline.
LEAD PRODUCT: BTX 1503 (MODERATE TO SEVERE ACNE) - Phase 2 clinical trial, page-18
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.5¢ |
Change
0.015(4.05%) |
Mkt cap ! $699.7M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 39.0¢ | 37.0¢ | $1.537M | 4.028M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 91664 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.5¢ | 100000 | 1 |
View Market Depth
| Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
| BOT (ASX) Chart |